Mather Group’s IceCure Medical ICCM Stock Holding History

Mather Group’s Portfolio ICCM Stock Details ICCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-53	Closed	-$1.71K	–	2243
2024 Q1	$1.71K	Buy	+53	New	+$2.07K	﹤0.01%	1567

Other funds holding ICCM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

KFG

Kingdom Financial Group Peoria, Arizona $349M AUM 12.25% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mather Group's ICCM Position: Q2 2024 in Review

Mather Group sold out of IceCure Medical (ICCM) in Q2 2024, closing a stake of 53 shares — an estimated $1.71K sold.

Mather Group first reported a position in ICCM in Q1 2024 and held it in 1 quarter. The position peaked at $1.71K in Q1 2024. 14 funds tracked by Wall St. Rank hold ICCM as of Q2 2024.

Mather Group reported no remaining IceCure Medical position as of Q2 2024 after selling out during the quarter.
Mather Group sold 53 IceCure Medical shares in Q2 2024, an estimated $1.71K.
Mather Group first reported a position in IceCure Medical in Q1 2024 and held it in 1 quarter.
Mather Group's IceCure Medical position peaked at $1.71K in Q1 2024.
14 funds tracked by Wall St. Rank held IceCure Medical as of Q2 2024.

Based on Mather Group's 13F filing for Q2 2024, filed 9 Jul 2024.